CADL - Candel Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Needham,
United States
Type: Equity
CADL price evolution
CADL
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $36.8 | $45.1 | $53.36 | $61.88 |
| Long term investments | ||||
| Property, plant & equipment | $4.02 | $4.6 | $4.92 | $5.1 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $41.2 | $50.1 | $58.71 | $67.24 |
| Current liabilities | ||||
| Accounts payable | $0.42 | $0.3 | $0.48 | $0.59 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $14.18 | $10.3 | $8.16 | $5.24 |
| Long term debt | $12.38 | $15.1 | $17.4 | $19.7 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $28.46 | $27 | $27.94 | $27.59 |
| Shareholders' equity | ||||
| Retained earnings | -$137.03 | -$125.9 | -$117.5 | -$107.88 |
| Other shareholder equity | ||||
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $36.8 | $71.94 | $84.94 | $35.15 |
| Long term investments | ||||
| Property, plant & equipment | $4.02 | $5.48 | $3.84 | $2.79 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $41.2 | $77.69 | $89.2 | $38.28 |
| Current liabilities | ||||
| Accounts payable | $0.42 | $0.38 | $1.59 | $0.92 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $14.18 | $5.62 | $5.36 | $4.71 |
| Long term debt | $12.38 | $20.85 | $0.56 | $0.48 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $28.46 | $29.98 | $25.07 | $12.78 |
| Shareholders' equity | ||||
| Retained earnings | -$137.03 | -$99.09 | -$80.3 | -$44.17 |
| Other shareholder equity | ||||
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $10.12 | $8.66 | $9.58 | $9.63 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | -$0.26 | -$0.17 | -$0.19 | $0.1 |
| Net income | ||||
| Net income | -$11.1 | -$8.44 | -$9.61 | -$8.8 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.13 | $0.12 | ||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $37.99 | $34.85 | $25.85 | |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | -$0.51 | -$0.49 | -$0.05 | |
| Net income | ||||
| Net income | -$37.94 | -$18.79 | -$36.12 | |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0.28 | -$0.25 | -$0.15 | $0.02 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$0.12 | |||
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$34.64 | -$27.07 | -$18.16 | -$10.8 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0.28 | -$1.3 | -$1.83 | |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$0.12 | $19.97 | $71.8 | |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$34.65 | -$12.75 | $47.75 | |
News
Fundamentals
| Market cap | $237.96M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 29.09M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$37.95M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -6.27 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$1.30 |
|---|---|
| ROA | -69.87% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.59 |
| Quick ratio | N/A |